383 related articles for article (PubMed ID: 31533771)
41. Skeletal characteristics associated with homozygous and heterozygous WNT1 mutations.
Palomo T; Al-Jallad H; Moffatt P; Glorieux FH; Lentle B; Roschger P; Klaushofer K; Rauch F
Bone; 2014 Oct; 67():63-70. PubMed ID: 25010833
[TBL] [Abstract][Full Text] [Related]
42. Mortality and morbidity in patients with osteogenesis imperfecta in Denmark.
Folkestad L
Dan Med J; 2018 Apr; 65(4):. PubMed ID: 29619932
[TBL] [Abstract][Full Text] [Related]
43. Zoledronic acid treatment in children with osteogenesis imperfecta.
Vuorimies I; Toiviainen-Salo S; Hero M; Mäkitie O
Horm Res Paediatr; 2011; 75(5):346-53. PubMed ID: 21293106
[TBL] [Abstract][Full Text] [Related]
44. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
Zacharin M; Kanumakala S
J Pediatr Endocrinol Metab; 2004 Nov; 17(11):1511-7. PubMed ID: 15570988
[TBL] [Abstract][Full Text] [Related]
45. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
[TBL] [Abstract][Full Text] [Related]
46. Therapy with pamidronate in children with osteogenesis imperfecta.
Marginean O; Tamasanu RC; Mang N; Mozos I; Brad GF
Drug Des Devel Ther; 2017; 11():2507-2515. PubMed ID: 28894358
[TBL] [Abstract][Full Text] [Related]
47. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
[TBL] [Abstract][Full Text] [Related]
48. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy.
Rauch F; Travers R; Glorieux FH
J Clin Endocrinol Metab; 2006 Feb; 91(2):511-6. PubMed ID: 16291701
[TBL] [Abstract][Full Text] [Related]
49. Skeletal clinical characteristics of osteogenesis imperfecta caused by haploinsufficiency mutations in COL1A1.
Ben Amor IM; Roughley P; Glorieux FH; Rauch F
J Bone Miner Res; 2013 Sep; 28(9):2001-7. PubMed ID: 23529829
[TBL] [Abstract][Full Text] [Related]
50. Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.
Trejo P; Rauch F
Osteoporos Int; 2016 Dec; 27(12):3427-3437. PubMed ID: 27492436
[TBL] [Abstract][Full Text] [Related]
51. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
52. Alendronate treatment in children with osteogenesis imperfecta.
Akcay T; Turan S; Guran T; Bereket A
Indian Pediatr; 2008 Feb; 45(2):105-9. PubMed ID: 18310788
[TBL] [Abstract][Full Text] [Related]
53. Responsiveness to pamidronate treatment is not related to the genotype of type I collagen in patients with osteogenesis imperfecta.
Kanno J; Saito-Hakoda A; Kure S; Fujiwara I
J Bone Miner Metab; 2018 May; 36(3):344-351. PubMed ID: 28528406
[TBL] [Abstract][Full Text] [Related]
54. Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation.
Blouin S; Fratzl-Zelman N; Glorieux FH; Roschger P; Klaushofer K; Marini JC; Rauch F
J Bone Miner Res; 2017 Sep; 32(9):1884-1892. PubMed ID: 28548288
[TBL] [Abstract][Full Text] [Related]
55. Alendronate treatment in osteogenesis imperfecta.
Madenci E; Yilmaz K; Yilmaz M; Coskun Y
J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
[TBL] [Abstract][Full Text] [Related]
56. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
[TBL] [Abstract][Full Text] [Related]
57. Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
Falk MJ; Heeger S; Lynch KA; DeCaro KR; Bohach D; Gibson KS; Warman ML
Pediatrics; 2003 Mar; 111(3):573-8. PubMed ID: 12612238
[TBL] [Abstract][Full Text] [Related]
58. Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Arponen H; Vuorimies I; Haukka J; Valta H; Waltimo-Sirén J; Mäkitie O
J Neurosurg Pediatr; 2015 Mar; 15(3):313-20. PubMed ID: 25559924
[TBL] [Abstract][Full Text] [Related]
59. Impact of alendronate on quality of life in children with osteogenesis imperfecta.
Seikaly MG; Kopanati S; Salhab N; Waber P; Patterson D; Browne R; Herring JA
J Pediatr Orthop; 2005; 25(6):786-91. PubMed ID: 16294137
[TBL] [Abstract][Full Text] [Related]
60. Denosumab use in osteogenesis imperfecta: an update on therapeutic approaches.
Majdoub F; Ferjani HL; Nessib DB; Kaffel D; Maatallah K; Hamdi W
Ann Pediatr Endocrinol Metab; 2023 Jun; 28(2):98-106. PubMed ID: 37401056
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
